Finance

Lists
9926:HKG
Akeso Inc
91,30 HKD
+0,94%
(+0,85) 1D
16 ოქტ, 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 9926...
Open
92,15 HKD
High
95,30 HKD
Low
90,15 HKD
Mkt. cap
84,10 მლრდ.
Avg. vol.
10,45 მლნ.
Volume
11,09 მლნ.
52-wk high
156,00 HKD
52-wk low
80,20 HKD
EPS
-1,24 HKD
No. of employees
4 ათ.
Open
92,15 HKD
High
95,30 HKD
Low
90,15 HKD
Mkt. cap
84,10 მლრდ.
Avg. vol.
10,45 მლნ.
Volume
11,09 მლნ.
52-wk high
156,00 HKD
52-wk low
80,20 HKD
EPS
-1,24 HKD
No. of employees
4 ათ.
News stories
From web sources and news partners
The Fintech Times
The Fintech Times
·
41 წუთის წინ
First Digital to List on Nasdaq via SPAC Deal at $250m Valuation
Yahoo Finance
Yahoo Finance
·
1 საათის წინ
Anthropic IPO Buzz Has Investors Watching Nasdaq Stock And ECM Fee Winners
BeInCrypto
BeInCrypto
·
1 საათის წინ
Black Monday Fears Fade as Nasdaq Futures Rally After Friday Selloff
Bloomberg.com
Bloomberg.com
·
4 საათის წინ
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Profile
Akeso, Inc is a publicly listed Chinese biopharmaceutical company that is headquartered in Zhongshan, Guangdong. It is best known for developing Ivonescimab, a cancer treatment antibody. Wikipedia
About Akeso Inc
CEOმიშელ შა | მიშელ შა
Employees4,08 ათ.
Founded19 მარ. 2012
Headquarters-
Sector-
Websiteakesobio.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
822,37 მლნ.
822,37 მლნ.
902,84 მლნ.
902,84 მლნ.
Cost of goods sold
191,35 მლნ.
191,35 მლნ.
264,27 მლნ.
264,27 მლნ.
Cost of revenue
191,35 მლნ.
191,35 მლნ.
264,27 მლნ.
264,27 მლნ.
Research and development expenses
421,91 მლნ.
421,91 მლნ.
391,66 მლნ.
391,66 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
464,36 მლნ.
464,36 მლნ.
477,58 მლნ.
477,58 მლნ.
Operating expense
883,23 მლნ.
883,23 მლნ.
926,32 მლნ.
926,32 მლნ.
Total operating expenses
1,07 მლრდ.
1,07 მლრდ.
1,19 მლრდ.
1,19 მლრდ.
Operating income
-252,21 მლნ.
-252,21 მლნ.
-287,75 მლნ.
-287,75 მლნ.
Other non operating income
29,10 მლნ.
29,10 მლნ.
24,64 მლნ.
24,64 მლნ.
EBT including unusual items
-276,45 მლნ.
-276,45 მლნ.
-221,95 მლნ.
-221,95 მლნ.
EBT excluding unusual items
-276,19 მლნ.
-276,19 მლნ.
-226,43 მლნ.
-226,43 მლნ.
Income tax expense
-192,50 ათ.
-192,50 ათ.
1,68 მლნ.
1,68 მლნ.
Effective tax rate
0,07%
0,07%
-0,75%
-0,75%
Other operating expenses
-3,04 მლნ.
-3,04 მლნ.
57,08 მლნ.
57,08 მლნ.
Net income
-271,47 მლნ.
-271,47 მლნ.
-212,11 მლნ.
-212,11 მლნ.
Net profit margin
-33,01%
-33,01%
-23,49%
-23,49%
Earnings per share
-
-
-
-
Interest and investment income
84,42 მლნ.
84,42 მლნ.
74,56 მლნ.
74,56 მლნ.
Interest expense
-33,81 მლნ.
-33,81 მლნ.
-31,66 მლნ.
-31,66 მლნ.
Net interest expenses
50,61 მლნ.
50,61 მლნ.
42,90 მლნ.
42,90 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-187,68 მლნ.
-187,68 მლნ.
-210,51 მლნ.
-210,51 მლნ.
Gain or loss from assets sale
-1,00 ათ.
-1,00 ათ.
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები